Division of Allergy & Immunology, Children's National Health System, Washington, DC, USA.
Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA.
Br J Haematol. 2019 Oct;187(2):206-218. doi: 10.1111/bjh.16053. Epub 2019 Jun 20.
Viral infections are a serious cause of morbidity and mortality following haematopoietic stem cell transplantation (HSCT). Adoptive cellular therapy with virus-specific T cells (VSTs) has been successful in preventing or treating targeted viruses in prior studies, but the composition of ex vivo expanded VST and the critical cell populations that mediate antiviral activity in vivo are not well defined. We utilized deep sequencing of the T-cell receptor beta chain (TCRB) in order to classify and track VST populations in 12 patients who received VSTs following HSCT to prevent or treat viral infections. TCRB sequencing was performed on sorted VST products and patient peripheral blood mononuclear cells samples. TCRB diversity was gauged using the Shannon entropy index, and repertoire similarity determined using the Morisita-Horn index. Similarity indices reflected an early change in TCRB diversity in eight patients, and TCRB clonotypes corresponding to targeted viral epitopes expanded in eight patients. TCRB repertoire diversity increased in nine patients, and correlated with cytomegalovirus (CMV) viral load following VST infusion (P = 0·0071). These findings demonstrate that allogeneic VSTs can be tracked via TCRB sequencing, and suggests that T-cell receptor repertoire diversity may be critical for the control of CMV reactivation after HSCT.
病毒感染是造血干细胞移植(HSCT)后发病率和死亡率的一个严重原因。在先前的研究中,利用病毒特异性 T 细胞(VST)的过继细胞疗法已成功预防或治疗了靶向病毒,但体外扩增的 VST 组成和介导体内抗病毒活性的关键细胞群体尚未明确界定。我们利用 T 细胞受体β链(TCRB)的深度测序,对 12 名接受 VST 以预防或治疗病毒感染的 HSCT 后患者的 VST 群体进行分类和跟踪。对分选的 VST 产物和患者外周血单核细胞样本进行 TCRB 测序。使用香农熵指数评估 TCRB 多样性,并使用 Morisita-Horn 指数确定库相似性。相似性指数反映了 8 名患者 TCRB 多样性的早期变化,并且对应于靶向病毒表位的 TCRB 克隆型在 8 名患者中扩增。9 名患者的 TCRB 库多样性增加,与 VST 输注后巨细胞病毒(CMV)病毒载量相关(P=0·0071)。这些发现表明,通过 TCRB 测序可以跟踪同种异体 VST,并表明 T 细胞受体库多样性可能是控制 HSCT 后 CMV 再激活的关键。